title: Induction of pulmonary thromboembolism by neutrophil elastase in collagen-induced arthritis mice and effect of recombinant human soluble thrombomodulin.
abstract: We previously reported that during total knee arthroplasty in rheumatoid arthritis (RA) patients, the use of tourniquet might promote local release of neutrophil elastase (NE) from neutrophils, which may contribute to the development of pulmonary thromboembolism (PTE) and tissue injury. The aim of this study was to develop PTE by the use of NE in a mouse model of collagen-induced arthritis (CIA) and investigate the relationship between thrombus and endothelial cells as well as the effect of recombinant human soluble thrombomodulin (rhs-TM) in reducing the risk of PTE. Male DBA/1J mice were injected intracutaneously at several sites with an emulsion containing bovine collagen and later a booster shot to produce CIA mice. Subsequently, NE was injected intravenously 2 times a day for 3 days and after a further 4 days, mice were sacrificed. A group of mice received rhs-TM injections prior to NE injections. We divided the mice into four groups of normal, CIA control, CIA + NE, and CIA + rhs-TM + NE mice and evaluated thrombus formation status. All CIA + NE mice developed PTE. In contrast, no thrombosis was found in normal control, CIA control and CIA + rhs-TM + NE mice. Plasma thrombin level, fibrinogen expression and neutrophil count were increased in CIA + NE mice. Double staining for anticoagulant TM and procoagulant von Willebrand factor (vWF) in pulmonary endothelial cells in normal mice showed a TM-dominant expression while in both CIA control and CIA + NE mice a vWF-dominant expression compatible with coagulant status was observed. Injection of rhs-TM into CIA + NE mice resulted in a phenotypic conversion of endothelial cells from vWF-dominant to TM-dominant expression and a reduction in fibrinogen deposition. These findings demonstrate that by repeated use of NE in CIA mice, it is feasible to produce PTE and to study its pathogenesis and that rhs-TM reduces the risk of PTE. We suggest that in surgical operations of upper and lower extremities in RA patients, the use of a tourniquet should be avoided as it may trigger NE release.
authors.affiliation: Department of Molecular Pathology, Institute of Development and Aging Sciences, Nippon Medical School, Graduate School of Medicine, Nakahara-ku, Kawasaki, Japan.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Matsuoka
authors.forename: Enjing
authors.initials: E
authors.lastname: Jin
authors.forename: Akitoshi
authors.initials: A
authors.lastname: Tachihara
authors.forename: Mohammad
authors.initials: M
authors.lastname: Ghazizadeh
authors.forename: Atsuo
authors.initials: A
authors.lastname: Nakajima
authors.forename: Shinichi
authors.initials: S
authors.lastname: Yoshino
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Katayama
authors.forename: Oichi
authors.initials: O
authors.lastname: Kawanami
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000201:enzymology* / Q000601:surgery; D002417:Cattle; D042783:Endothelial Cells / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007275:Injections, Intravenous; D019272:Leukocyte Elastase / Q000378:metabolism* / Q000633:toxicity; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D011655:Pulmonary Embolism / Q000201:enzymology / Q000209:etiology / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D018180:Thrombomodulin / Q000008:administration & dosage / Q000627:therapeutic use*; D014111:Tourniquets / Q000009:adverse effects; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D011994:Recombinant Proteins; D018180:Thrombomodulin; D014841:von Willebrand Factor; D019272:Leukocyte Elastase